MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 33 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Reply to E.A. Rakha et al
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks, Kimberly H. Allison, John M.S. Bartlett, Michael Bilous +13 more
2015· letter· fr· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
32
citations
affunlabeled
Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue–Geile, Max S. Mano, Michael Untch +12 more
2020· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
32
citations
affunlabeled
Pain in Patients With Cancer
Pamela J. Goodwin, Éduardo Bruera, Martin R. Stockler
2014· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
32
citations
affunlabeled
Heterogeneity and Power in Clinical Biomarker Studies
Melania Pintilie, Vladimir V. Iakovlev, Anthony Fyles, David W. Hedley, Michael Milosevic, Rićhard P. Hill
2009· article· en· Journal of Clinical Oncology· Mathematics
machine prediction:candidate · metaresearchconsensus · metaresearch
31
citations
affunlabeled
RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).
Josep Tabernero, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu +13 more
2015· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
31
citations
affunlabeled
Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
Peter A. Fasching, Aditya Bardia, Vanesa Quiroga, Yeon Hee Park, Isabel Blancas, José Luis Alonso-Romero +14 more
2022· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
31
citations
affno abstractgemma · no categorygpt · no categorymodels agree
Breaking Bad News: More Than Just Guidelines
Walter F. Baile, Robert Buckman, Lidia Schapira, Patricia A. Parker
2006· letter· en· Journal of Clinical Oncology· Health Professions
machine prediction:candidate · noneconsensus · none
31
citations
affunlabeled
CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.
Markus Moehler, Yelena Y. Janjigian, Antoine Adenis, Jean-Sebastien Aucoin, Narikazu Boku, Ian Chau +11 more
2018· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
30
citations
affunlabeled
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
Srikala S. Sridhar, Thomas Powles, Shilpa Gupta, Miguel Ángel Climent, Jeanny B. Aragon‐Ching, Cora N. Sternberg +5 more
2023· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
30
citations

How this was built: Screen · Findings · About